ProfileGDS5678 / 1416106_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 82% 79% 81% 79% 77% 77% 76% 77% 82% 81% 80% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3054278
GSM967853U87-EV human glioblastoma xenograft - Control 25.9301382
GSM967854U87-EV human glioblastoma xenograft - Control 35.4733579
GSM967855U87-EV human glioblastoma xenograft - Control 45.8915981
GSM967856U87-EV human glioblastoma xenograft - Control 55.5336279
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1253677
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1286377
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1360676
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2805777
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9123982
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8520881
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6502980
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5443779
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.541479